Investment Analysts’ Weekly Ratings Changes for Sanara MedTech (SMTI)

Several brokerages have updated their recommendations and price targets on shares of Sanara MedTech (NASDAQ: SMTI) in the last few weeks:

• 8/11/2026 – Sanara MedTech was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/3/2026 – Sanara MedTech was downgraded by Freedom Capital from “strong-buy” to “hold”.
• 8/1/2026 – Sanara MedTech was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 7/30/2026 – Sanara MedTech was downgraded by Lake Street Capital from “buy” to “hold”. They now have a $35.00 price target on the stock.
• 7/30/2026 – Sanara MedTech was downgraded by HC Wainwright from “buy” to “neutral”. They now have a $35.00 price target on the stock, down from $36.00.
• 7/17/2026 – Sanara MedTech had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 7/4/2026 – Sanara MedTech was upgraded by Wall Street Zen from “buy” to “strong-buy”.

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.